Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review
Disclaimer: Pricing is subject to change
By the Scientific Editorial Team at GEK Lab
The lawsuits target Novo Nordisk, the manufacturer of Wegovy, accusing the company of failing to adequately warn users about the possible severe gastrointestinal side effects, such as stomach paralysis or gastroparesis and intestinal blockages
While the trial primarily examined cardiovascular outcomes in adults with obesity, the metabolic data showed significant improvements in blood sugar control, A1C levels, and progression rates toward diabetes in participants taking semaglutide 2.4 mg weekly (Lincoff AM, et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, New England Journal of Medicine , 2023)